Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)

Nishizawà, Yoshiki; Nakamura, Toshio; Ohta, Hiroaki; Kushida, Kazuhiro; Gorai, Itsuo; Shiraki, Masataka; Fukunaga, Masao; Hosoi, Takayuki; Miki, Takami; Chaki, Osamu; Ichimura, Schoichi; Nakatsuka, Kiyoshi; Miura, Masaru

doi:10.1007/s00774-004-0547-6

Cited by 117 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We excluded participants with diagnoses of lifetime bipolar disorder, chronic psychotic disorder or dementia, history of alcohol or substance abuse or dependence during the past 6 months, unstable medical illness, corticosteroid treatment, or any contraindication to venlafaxine. We assayed BTMs in participants who completed the acute treatment phase and both pre- and post- serum collections within the recommended 08:00 to 11:00 h time-frame for biomarker collection (Nishizawa et al 2005; Civitelli et al 2009; Shea et al 2013). Twenty-eight patients were receiving an SSRI prior to entering the study and discontinued this drug 2 weeks prior to beginning the open-label study treatment.…”

Section: Methodsmentioning

confidence: 99%

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

Garfield

Müller

Kennedy

et al. 2013

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Objectives Studies have reported an association between serotonin reuptake inhibitors (SRIs) and accelerated bone loss. Genetic variation in the serotonin system might modulate bone metabolism changes during SRI treatment. In a clinical trial we examined functional genetic polymorphisms of serotonin transporter and receptors involved in bone metabolism to determine whether they predict changes in bone metabolism during SRI treatment. Methods In 69 adults (age ≥ 60) participating in a 12-week, open-label trial of the SRI venlafaxine for major depression, serum markers of bone formation (P1NP) and resorption (β-CTX) were assayed before and after treatment. Participants were genotyped for putative high- versus low-expressing polymorphisms in the serotonin transporter (5HTTLPR) and 1B receptor (HTR1B) genes. Results Bone formation was significantly reduced with administration of venlafaxine in participants with the high-expressing 5HTTLPR genotype and those with the low-expressing HTR1B genotype. This primarily occurred in individuals with the combination of the high-expressing 5HTTLPR genotype and the low-expressing HTR1B genotype. Conclusions These preliminary findings indicate that genetic variation in the serotonin receptors predicts changes in bone metabolism during SRI use. If these results are replicated and clinically confirmed, we will have identified a genetic subgroup at high risk for deleterious bone outcomes with the use of SRIs.

show abstract

Section: Methodsmentioning

confidence: 99%

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

Garfield

Müller

Kennedy

et al. 2013

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…68 In addition, it should be noted that abnormal bone turnover marker values may indicate that a fracture has occurred within the previous 3 months, resulting in accelerated local bone metabolism. 70 Recent developments using an electrochemiluminescence automated method (Elecsys, Roche Diagnostics) to measure N-MID Osteocalcin and PINP (bone formation) and sCTx (bone resorption) with excellent intra-and interassay precisions (CV ≈ 5-8%) have improved the ability of bone turnover markers to monitor the individual response to antiresorptive or bone-forming therapies. 71 …”

Section: Bone Turnover Markersmentioning

confidence: 99%

Canadian Consensus Conference on Osteoporosis, 2006 Update

Brown¹,

Fortier²,

Frame

et al. 2006

Journal of Obstetrics and Gynaecology Canada

View full text Add to dashboard Cite

Objective-To provide guidelines for the health care provider on the diagnosis and clinical management of postmenopausal osteoporosis.Outcomes-Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis. Values-The quality of evidence is rated using the criteria described in the report of the Canadian Task Force on the Periodic Health Examination. Recommendations for practice are ranked according to the method described in this report.

show abstract

“…The precision was calculated as the coefficient of variation (% CV: 3.8%) in this series. According to the guidelines of the Japanese Osteoporosis Society, the reference ranges for Cre-normalized urinary NTX have been established using a commercially available enzyme immunoassay as: 9.3 to 54.3 nmol bone collagen equivalent (BCE)/nmol•Cre in premenopausal females, 14.3 to 89.0 nmol BCE/nmol•Cre in postmenopausal females, and 13.0 to 66.2 nmol BCE/nmol•Cre in males [17]. In addition, NTX values can suggest bone diseases (>54.3), metastatic bone tumor (>89.0), or abnormal calcium metabolism (>66.2 nmol BCE/nmol•Cre).…”

Section: Methodsmentioning

confidence: 99%

“…In addition, NTX values can suggest bone diseases (>54.3), metastatic bone tumor (>89.0), or abnormal calcium metabolism (>66.2 nmol BCE/nmol•Cre). Finally, the cutoff level of NTX that indicates high risk of fracture is 54.3 nmol BCE/nmol•Cre [17]. …”

Section: Methodsmentioning

confidence: 99%

Preoperative Bone Mineral Density and Bone Turnover in Women Before Primary Knee Arthroplasty

Ishii¹,

Noguchi²,

Sato³

et al. 2016

TOORTHJ

View full text Add to dashboard Cite

Purpose:The preoperative prevalence of osteoporosis and/or osteopenia and overall bone quality in prospective total knee arthroplasty (TKA) patients may affect the postoperative outcome after prosthetic insertion into the bone. The purpose of this study is to determine the baseline bone mineral density (BMD) and bone turnover in preoperative, female, primary TKA patients.Methods:We prospectively measured the lumbar spine and hip BMDs using dual-energy X-ray absorptiometry (DEXA) scans in a cohort of 119 knees (107 patients) one day before surgery. We also assessed bone turnover using urinary levels of N-telopeptide (NTX), a type I collagen crosslinker, normalized to creatinine.Results:The prevalence of osteoporosis by DEXA scan (T-score ≤ −2.5) among the TKAs was 12% in the spine and 10% in the hip. Eighty-three knees (70%) had osteopenia or osteoporosis of either the spine or hip. The mean T-score of the spine was −0.7 (SD 1.6), which is within normal limits, and of the hip was −1.2 (SD 1.0), which is defined as osteopenia. The mean Z-scores of 0.9 (SD 1.4) in the spine and 0.6 (SD 0.9) in the hip were positive. The median urinary NTX/creatinine ratio was elevated at 58.1 (interquartile range: 13.7 to 188.4).Conclusion:Based on Z-scores, the TKA patients had higher spine and hip BMDs than the age-matched general population. Elevated NTX levels may suggest a systemic or local abnormal bone turnover. Further study is needed to determine whether such turnover, as a type of patient-related medical systemic disorder, affects postoperative clinical outcomes.

show abstract

Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)

Cited by 117 publications

References 0 publications

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

Canadian Consensus Conference on Osteoporosis, 2006 Update

Preoperative Bone Mineral Density and Bone Turnover in Women Before Primary Knee Arthroplasty

Contact Info

Product

Resources

About